PostDose.

Guides

"Research Use Only" Peptides: What the FDA's 2026 Warning Letters Actually Say

A "not for human consumption" label does not make an injectable peptide legal. We read four 2026 FDA warning letters to online peptide sellers and summarize what the agency looks at, and what it means for choosing a Houston clinic.

Search for semaglutide, tirzepatide or retatrutide online and you will find vials sold with a disclaimer: “for research use only,” “not for human consumption.” The implication is that the label makes the sale legal. The FDA’s recent warning letters say otherwise, and they are public. We read four of them directly on fda.gov on October 16, 2026.

What the four letters have in common

The letters we read were issued by the FDA’s Center for Drug Evaluation and Research (CDER) to online sellers:

  • Gram Peptides — letter dated March 31, 2026 (reference 721806). The FDA reviewed the seller’s website from January to March 2026 and cited its retatrutide, tirzepatide and bacteriostatic water listings.
  • Wholesale Peptide — letter dated June 17, 2026 (reference 729447), after a May 2026 website review, citing “Prostamax” and gonadorelin.
  • Royal Peptides and TXP Innovations (Tex Peptides) — both dated August 24, 2026 (references 734884 and 735067), after July 2026 website reviews. Both list tirzepatide, semaglutide, retatrutide, SS-31, tesamorelin and PT-141; Royal Peptides’ letter also cites a product called “BIMORELIN,” and TXP’s cites its “Semaglutide (GLP-1 SEM)” and “Tirzepatide (GLP-2 TRZ)” listings.

In each, the FDA’s position is the same: the products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act, and selling them in interstate commerce violates sections 301(d) and 505(a).

The disclaimer does not decide it

The Gram Peptides letter is explicit. It acknowledges the seller’s “Research Use Only” and “not intended for human consumption, medical use, or veterinary use” statements, then says that “evidence obtained from your website establishes that your products are intended to be drugs for human use.” The FDA’s test is intended use (it cites 21 CFR 201.128), and it finds intent in the seller’s own marketing: descriptions of appetite suppression, insulin sensitivity, weight management and body-weight reduction. The August letters carry footnotes making the same point about their own “research use only” and “not for human or veterinary use” labels.

Bacteriostatic water gets the same treatment. The Gram Peptides letter says that selling it alongside peptides “demonstrates that you intend for your ‘Bacteriostatic Water for Injection’ to be used in combination for injection,” which makes the water itself a drug. The TXP letter says the same of water sold “to reconstitute the peptide products.”

The letters also state why the FDA treats this as serious: injectables “bypass some of the body’s key defenses against toxins and microorganisms.”

What these letters do not say

Accuracy matters on a medical topic, so some limits:

  • A warning letter is the FDA’s stated position about a specific firm’s website, not a court ruling. Each letter asks the firm to respond and warns that failure to do so “may lead to regulatory or legal action.”
  • We read four letters. We did not review every FDA action on peptides, and we have not verified any other enforcement action beyond these.
  • The letters concern sellers. None tells a patient what to do, and nothing here is medical advice.
  • Nothing in the letters addresses a licensed clinic dispensing a prescribed product through a licensed pharmacy. That is a different legal question, which our brand vs. compounded guide and the substance pages for semaglutide, tirzepatide, BPC-157 and ipamorelin cover with their own FDA sources.

What this means when you pick a clinic

A clinic’s status and a vendor’s status are different things, but research-grade peptides leak into clinic menus. In our audit, 80 clinics were evaluated and 41 were excluded outright; our exclusion log shows repeated cases of Houston-area clinics whose programs were built around unapproved “research” peptides such as CJC-1295, ipamorelin or BPC-157. Practical checks that follow from the FDA letters:

  1. Ask what the product is and who makes it. Brand-name drugs come from the manufacturer’s supply chain; compounded drugs must come from a licensed pharmacy. “Peptide vial, research grade” is neither.
  2. Be suspicious of dose calculators and reconstitution instructions paired with a “research” label. The FDA cites exactly that combination as evidence of intended human use.
  3. Verify the prescriber and pharmacy yourself. Our verification walkthrough takes minutes.
  4. Watch the red flags in the product itself. See the FDA’s compounded GLP-1 warning signs.

We list only clinics that pass our four-point standard, described in full on our methodology page. As of today, six clinics carry a verified status; see the verified Houston clinics. We do not link to or list “research use only” vendors.

Sources: FDA warning letters, all read October 16, 2026: Gram Peptides, 721806, March 31, 2026; Wholesale Peptide, 729447, June 17, 2026; Royal Peptides, 734884, August 24, 2026; TXP Innovations (Tex Peptides), 735067, August 24, 2026. Audit counts from the PostDose audit and data/excluded.md.